Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)

John Allan, Daniel Helbig,Sarah Rutherford,Erin Mulvey, Katie Greig, Sandra Stewart, Melissa LaPinta, Leslie Rudolph, Orel Agami, Melanie Bernstein,Jia Ruan,John Leonard,Peter Martin,Richard Furman

Blood(2023)

引用 0|浏览3
暂无评分
摘要
Background:
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要